Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFSF11 | O14788 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785673 | 1.00 | TNFSF11 (0.42) | TNFSF11MTNR1AMTNR1BELANEKDM4E | |
| SCHEMBL16785680 | 0.79 | ELANE (0.39) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL16785665 | 0.79 | ACHE (0.53) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL16785667 | 0.79 | ACHE (0.53) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL16785668 | 0.78 | ELANE (0.53) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL16785682 | 0.78 | CYP3A4 (0.38) | TNFSF11MTNR1AMTNR1BELANEKDM4E | |
| SCHEMBL16785681 | 0.78 | ELANE (0.38) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL18200168 | 0.78 | MTNR1A (0.48) | TNFSF11MTNR1AMTNR1BELANEKDM4E | |
| SCHEMBL16785678 | 0.78 | ELANE (0.38) | MTNR1AMTNR1BELANEKDM4EALDH1A1 | |
| SCHEMBL16785672 | 0.75 | ACHE (0.55) | ELANEKDM4EALDH1A1GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365513-B2 | Fullerene derivative, and method of preparing the same | RICOH COMPANY, LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365513-B2 | Fullerene derivative, and method of preparing the same | RICOH COMPANY, LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150158814-A1 | FULLERENE DERIVATIVE, AND METHOD OF PREPARING THE SAME | RICOH COMPANY, LTD. (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158814-A1 | FULLERENE DERIVATIVE, AND METHOD OF PREPARING THE SAME | RICOH COMPANY, LTD. (JP) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158814-A1 | FULLERENE DERIVATIVE, AND METHOD OF PREPARING THE SAME | NCL, PFDN2, NUP50 | TNFSF11 4873/4885MTNR1A 4534/4885MTNR1B 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.